A data safety monitoring board recommended pausing the Phase 2b test of Pliant’s bexotegrast, an experimental treatment for idiopathic pulmonary fibrosis. The move follows a prespecified data review, the company said.
Insilico Medicine’s idiopathic pulmonary fibrosis drug led to dose-dependent improvement in lung function in a mid-stage study. Meanwhile, Pliant Therapeutics and PureTech Health are also making Phase 2 progress while Boehringer Ingelheim is planning a regulatory submission supported by its IPF drug’s Phase 3 data.
The ongoing nursing shortage facilitates high turnover rates since nurses know they won’t have difficulties finding new jobs. In order to retain and attract staff, it’s in a facility’s best interest to understand what nurses want.
Contineum Therapeutics plans to spend most of its IPO cash on clinical testing of a lead drug candidate in development for idiopathic pulmonary fibrosis and multiple sclerosis. This small molecule blocks a competitive target pursued by several other companies, including Bristol Myers Squibb and AbbVie.
Contineum Therapeutics, which emerged from a Verant Ventures startup creation engine, has filed paperwork for an IPO. The biotech’s clinical-stage pipeline spans multiple sclerosis, idiopathic pulmonary fibrosis, and depression.
FibroGen drug pamrevlumab has failed a Phase 3 study testing it in the chronic lung disorder idiopathic pulmonary fibrosis. It’s the second trial failure for the drug in the past month and the company’s third Phase 3 failure in the past two months.
AbbVie acquired DJS Antibodies for $255 million up front. The U.K.-based biotech’s lead program is an antibody drug in preclinical development for idiopathic pulmonary fibrosis, a chronic lung disorder with few FDA-approved treatments.
Help shape the future of healthcare benefits by sharing your insights.
Endeavor BioMedicines aims to kill two birds with one stone—that stone being a small molecule drug. Taladegib targets a cell signaling pathway associated with both cancer and idiopathic pulmonary fibrosis, and the biotech will apply its Series B round toward clinical tests of the molecule on both fronts.
A NeRRE Therapeutics drug that failed a clinical trial for refractory or unexplained chronic cough is getting a second shot as a potential treatment for chronic cough in patients with idiopathic pulmonary fibrosis, a rare lung disorder. The biotech raised £20M to proceed with Phase 2 testing.
The collaboration includes six drugs in development and more than 20 in preclinical development. It also amends an existing four-year-old partnership the two companies had regarding the autoimmune disease drug filgotinib.
Health tech incubator MATTER has joined forces with Three Lakes Partners to launch an innovation challenge to meet the needs of idiopathic pulmonary fibrosis patients.
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
It plans to bring its idiopathic pulmonary fibrosis small molecule to the clinic in the next two years.
#MIS2014 Innovation #5 – antibody drug conjugates. Again! Idea around for 30 years, but antibodies better, humanized, understand targets. — Meghana Keshavan (@meghanakeshavan) October 29, 2014 The Cleveland Clinic just announced its top 10 medical innovations for 2015 – a long anticipated and often-prescient listing of the most gamechanging new health techs. This just in: […]
MedCity News has partnered with BioCrossroads to provide coverage focused on Indiana’s next generation of growth and innovation in life sciences. Indianapolis startup ImmuneWorks is developing drugs to treat lung transplant patients, idiopathic pulmonary fibrosis and other fibrotic lung diseases. The 8-year-old company was founded by two researchers at the Indiana University School of Medicine […]